1800 OWENS STREET, SAN FRANCISCO, CA
PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Appoints Aziz Sawaf as Chief Financial Officer
Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CFO Departure - Jason O’Byrne Steps Down from Vir Biotechnology
Board Expansion; Timothy Coughlin Appointed as Class III Director
Material disclosure
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
S-1MEF
Correspondence
Submission Upload